Synthesizing Multiple Sources Practice Test

They agree embryo editing is already routine and safe, so ethical debate is largely obsolete and delays are unjustified.

They reject all medical uses of CRISPR, including in non-reproductive cells, because any editing necessarily alters heredity.

They argue the central problem is cost alone, implying safety and consent questions are minor compared with insurance coverage.

They converge on medical promise but stress uncertainty and ethics, differing on whether strict moratoria or tightly regulated trials are preferable.